

DATE:

January 30, 2007SHEET 1 of 1

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified)
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

BBC128USC1

SERIAL NO.

10/828,607

APPLICANT

Carl M. Mendel, et al.

FILING DATE

April 21, 2004

GROUP

1614 EXAMINER L.A. ROVDS

U.S. PATENT DOCUMENTS

EXAM. INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
LAR	A1	4,522,828	06/11/1985	Jeffery, et al.	—	—	—
LAR	A2	4,939,175	07/03/1990	Ukai, et al.	—	—	—
LAR	A3	5,166,207	11/24/1992	Smith	—	—	—
LAR	A4	5,436,272	07/25/1995	Scheinbaum	—	—	—
LAR	A5	5,877,188	03/02/1999	McCullough, et al.	—	—	—
LAR	A6	6,004,927	12/21/1999	Benet, et al.	—	—	—
LAR	A7	6,323,242	11/27/2001	Mueller	—	—	—

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

EXAM. INITIAL		DOCUMENT NUMBER	PUBLI- CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
LAR	B1	0 230 742	26.09.1990	EP	—	—	—	—
LAR	B2	2 098 602	24.11.1982	GB	—	—	—	—
LAR	B3	88/06444	07.09.1988	WO	—	—	—	—
LAR	B4	90/06110	14.06.1990	WO	—	—	—	—
LAR	B5	95/20949	10.08.1995	WO	—	—	—	—
LAR	B6	98/41528	24.09.98	WO	—	—	—	—

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

EXAM. INITIAL	C1	Adedeyin, A., et al., "Chloroquine modulation of specific metabolizing enzymes activities - investigation with selective five drug cocktail", <i>Br. J. Clin. Pharmacol.</i> , 46:215-219 (1998)
	C2	Risomgarden, Z.T., "The European Association for the Study of Diabetes Annual Meeting, 1998: The UK Prospective Diabetes Study and other topics in type 2 diabetes", <i>Diabetes Care</i> , 22(6):980-995 (1999)
	C3	Hsu, A., et al., "Ritonavir: Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents", <i>Clin. Pharmacokinet.</i> , 35(4):275-291 (1998)
	C4	Jos, A.A.B., et al., "Dose-Dependent Pharmacokinetic Interaction of Clozapine and Paroxetine in an Extensive Metabolizer", <i>Psychopharmacol.</i> , 130:268-270 (1997)
	C5	Euroott, C., "The Effects of the Genetic Absence and Inhibition of CYP2D6 on the Metabolism of Codeine and Its Derivatives, Hydrocodone and Oxycodeone", <i>Anesth Prog.</i> , 45:154-156 (1999)

EXAMINER

DATE CONSIDERED

10 JULY 07

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)